tetano
Editor, Senior Moderator
Cureus
. 2022 Feb 26;14(2):e22640.
doi: 10.7759/cureus.22640. eCollection 2022 Feb.
Severe Multisystem Inflammatory Syndrome Associated With SARS-CoV-2 in a 31-Year-Old Male Patient: The First Clinical Case Report From the Republic of Cyprus
Despina Markoulaki[SUP] 1 [/SUP], Stelios Iordanou[SUP] 1 [/SUP], Demetris Koukios[SUP] 1 [/SUP], Ioanna Christoldoulou[SUP] 1 [/SUP], Panos Papadopoulos[SUP] 1 [/SUP], Chrystalla Timiliotou-Matsentidou[SUP] 1 [/SUP]
Affiliations
Abstract
Multisystem inflammatory syndrome (MIS) in adults associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is increasingly reported in published literature, although published reports remain sparse. In this report, we describe our first experience with a 31-year-old Caucasian male who developed severe MIS 31 days after a mild SARS-CoV-2 infection. The patient developed fever, elevated C-reactive protein (CRP), procalcitonin (PCT), reduced ejection fraction (EF), and shock. After extensive diagnostic work-up, nothing was found to justify his shock manifestation. A similar treatment to MIS in children (MIS-C) with immunoglobulins, corticosteroids, and anticoagulants led to a remarkable clinical improvement. MIS in adults (MIS-A) can be fatal. The early identification of MIS plays a crucial role in the prompt initiation of suitable treatment. Therefore, differential diagnosis and exclusion of other causes of illness are of priority. We believe that MIS in children treatment guidelines can be reformed in a way to include MIS in adults as well.
Keywords: acute respiratory distress syndrome [ards]; covid-19 mis-c; intensive care unit; multisystem inflammatory syndrome in adults [mis-a]; sars-cov-2 (severe acute respiratory syndrome coronavirus -2).
. 2022 Feb 26;14(2):e22640.
doi: 10.7759/cureus.22640. eCollection 2022 Feb.
Severe Multisystem Inflammatory Syndrome Associated With SARS-CoV-2 in a 31-Year-Old Male Patient: The First Clinical Case Report From the Republic of Cyprus
Despina Markoulaki[SUP] 1 [/SUP], Stelios Iordanou[SUP] 1 [/SUP], Demetris Koukios[SUP] 1 [/SUP], Ioanna Christoldoulou[SUP] 1 [/SUP], Panos Papadopoulos[SUP] 1 [/SUP], Chrystalla Timiliotou-Matsentidou[SUP] 1 [/SUP]
Affiliations
- PMID: 35237494
- PMCID: PMC8882222
- DOI: 10.7759/cureus.22640
Abstract
Multisystem inflammatory syndrome (MIS) in adults associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is increasingly reported in published literature, although published reports remain sparse. In this report, we describe our first experience with a 31-year-old Caucasian male who developed severe MIS 31 days after a mild SARS-CoV-2 infection. The patient developed fever, elevated C-reactive protein (CRP), procalcitonin (PCT), reduced ejection fraction (EF), and shock. After extensive diagnostic work-up, nothing was found to justify his shock manifestation. A similar treatment to MIS in children (MIS-C) with immunoglobulins, corticosteroids, and anticoagulants led to a remarkable clinical improvement. MIS in adults (MIS-A) can be fatal. The early identification of MIS plays a crucial role in the prompt initiation of suitable treatment. Therefore, differential diagnosis and exclusion of other causes of illness are of priority. We believe that MIS in children treatment guidelines can be reformed in a way to include MIS in adults as well.
Keywords: acute respiratory distress syndrome [ards]; covid-19 mis-c; intensive care unit; multisystem inflammatory syndrome in adults [mis-a]; sars-cov-2 (severe acute respiratory syndrome coronavirus -2).